Literature DB >> 660266

Functional treatment of acromegaly by transsphenoidal microsurgery.

J García-Uría, J M del Pozo, G Bravo.   

Abstract

The authors have analyzed the results from 41 acromegalic patients who underwent transsphenoidal surgery. In 31 patients, postoperative growth hormone (GH) levels fell and remained below 10 ng/ml. This represents an endocrinological "cure" of 78%. In the remaining 10 cases, postoperative GH values have not stabilized below 10 ng/ml, although seven show some clinical improvement. The results were particularly good in those cases of localized adenomas, which allowed a selective removal while maintaining pituitary function within normal limits in 65.5% of cases. The postoperative GH level in this group fell and remained below 10 ng/ml in more than 90% of cases. Four patients required reoperation to normalize the GH levels which had not been sufficiently modified after the first operation; only one of them remained with plasma GH levels above normal limits. There were no deaths in this series. Rhinorrhea occurred as a postsurgical complication in four cases. In three this disappeared with bed rest and lumbar drainage; in the other, surgical repair was necessary. The occurrence of surgical complications has decreased as our experience has increased, and the need for reoperation has been unusual after the first year of our study.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 660266     DOI: 10.3171/jns.1978.49.1.0036

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  2 in total

1.  Acromegaly: surgical results in 548 patients.

Authors:  Cecilia Fernández Mateos; Maria García-Uria; Tomás Lucas Morante; José García-Uría
Journal:  Pituitary       Date:  2017-10       Impact factor: 4.107

2.  Recovery of visual and endocrine function following transsphenoidal surgery of large nonfunctioning pituitary adenomas.

Authors:  M Marazuela; B Astigarraga; A Vicente; J Estrada; C Cuerda; J García-Uría; T Lucas
Journal:  J Endocrinol Invest       Date:  1994-10       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.